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Colorectal cancer (CRC) is a major public health problem. Early CRC detection, pretherapeutic responsiveness
prediction, and postoperative micrometastasis monitoring are the hallmarks for successful CRC treatment. Here,
the methodologies used for detecting circulating tumor cells (CTCs) from CRC are reviewed. In addition to the
traditional CRC biomarkers, the persistent presence of posttherapeutic CTCs indicates resistance to adjuvant
chemotherapy and/or radiotherapy; hence, CTCs also play a decisive role in the subsequent relapse of CRC.
Moreover, the genetic and phenotypic profiling of CTCs often differs from that of the primary tumor; this
difference can be used to select the most effective targeted therapy. Consequently, studying CTCs can potentially
individualize treatment strategies for patients with CRC. Therefore, CTC detection and characterization may be
valuable tools for refining prognosis, and CTCs can be used in a real-time tumor biopsy for designing individually
tailored therapy against CRC.
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Colorectal cancer (CRC) is the second and third most commonly
diagnosed cancer among women and men worldwide, respectively,
with more than 1.2 million new cases and 608,700 deaths being
estimated in 2008 [1]. Early CRC detection is the hallmark of
successful treatment. Fecal occult blood tests show high false-positive
rates, and other diagnostic methods such as double-contrast barium
enemas, flexible sigmoidoscopy, and colonoscopy are highly invasive;
therefore, these are not preferable for broad screening [2–5]. With
recent advances in imaging technology and other diagnostic
modalities, including computed tomography and magnetic resonance
imaging, sufficient sensitivity (e.g., detection of tumor nodules of ≥1
cm in diameter) has been achieved; however, high costs and radiation
exposure restrict their use for screening [6,7]. Therefore, more
reliable, relatively inexpensive, and noninvasive methods are required
for early diagnosis of CRC.
Curative surgery remains the mainstay of CRC therapy; however,
approximately half of the patients receiving surgery alone ultimately
relapse and die of metastatic CRC (mCRC) [8]. Although the treatment
of advanced CRC using a multidisciplinary approach has improved
considerably, patients with postoperative relapse or mCRC still have
poor prognosis [9]. The recurrence rate was 33.6% in stage III colon
cancer patients receiving a postoperative FOLFOX4 [(oxaliplatin +
leucovorin + fluorouracil (FU)] regimen during a 5-year MOSAIC
follow-up period [10] and 27.8% in stage II and III colon cancer
patients using the same adjuvant regimen in a 4-year National Surgical
Adjuvant Breast and Bowel Project (NSABP) protocol C-07 study [11].
For several decades, efforts have been expended on the early detection of
recurrent tumors to ensure adequate and effective treatment and
improve patients' prognoses [12]. Undetected micrometastatic tumor
cells with reduced response to chemotherapeutic regimens contribute to
the failure of primary curative surgery with subsequent adjuvant
chemotherapy in patients with advanced CRC [13].
Although cancer biomarker discovery has rapidly proliferated and
numerous biomarkers have been reported, relatively few of these are
in clinical use. Some biomarkers do not translate into clinical practice,
probably because of inherent technical challenges in their testing; in
most cases, this failure is engendered by overlaps in the ranges of
normal individuals and cancer patients, hindering an accurate
distinction. Identifying specific colon tumor-associated molecular
markers and developing accurate assays for effective disease
monitoring would considerably improve the early diagnosis of
recurrence, leading to more effective treatment [14]. Tumor relapse
after curative resection of CRC and adjuvant chemotherapy is
attributed to tumor cell dissemination and resistance to adjuvant
chemotherapy. Heterogeneous tumor behaviors and individual
patient responses to chemotherapeutic agents lead to variable
outcomes. Therefore, the detection of tumor-shed cells in the
bloodstream is highly critical for early identification of postoperative
and/or adjuvant chemotherapeutic patients with CRC requiring
further optimal therapy [15].
Primary tumors begin shedding neoplastic cells into the circulation
at an early stage [16,17], and approximately 106 cells are shed daily
per gram of tumor [18]. The presence of circulating tumor cells
(CTCs) was confirmed with Engell's documentation of cancer cells in
the circulation in 1955 [19]. CTCs constitute a heterogeneous
population of cells with different biological characteristics and are
often different from their respective primary counterparts. Because
early detection is one of the most effective means of reducing cancermortality, CTCs can potentially aid in achieving an early noninvasive
early diagnosis of cancer [20,21]. The genetic and phenotypic
profiling of CTCs often differs from that of primary tumors, and it
can be used to select the most effective targeted therapy [22]. CTC
characterization at different time points during the course of disease
may provide useful predictive information for selecting the most
appropriate treatment. Moreover, CTC detection is correlated with
disease stage, relapse rate, and survival.
TraditionalClinicalOutcome Indicators amongPatients
with CRC
Clinicopathological Indicators
The anatomic extent of tumor (pTNM staging) and the residual
tumor status following treatment (residual tumor or R classification)
are the strongest predictors of outcome for patients with CRC. A
careful pTNM classification enables an accurate estimation of
prognosis; therefore, it can be considered the gold standard for
analyzing the results of any treatment [23]. The 5-year survival rates
observed after R0 resection of CRC were 55% to 60%, but for R1
and R2 resections, they were approximately 5% each [23].
Similar data were reported by a prospective multicenter observa-
tional study conducted by the German Study Group Colo-Rectal
Carcinoma: The most critical tumor-related prognostic factors
following surgical treatment were residual tumor status and anatomic
extent, as described through the Union for International Cancer
Control (UICC) pTNM stage grouping [24]. The locoregional
recurrence rate is influenced by tumor-related (e.g., stage and tumor
site) and treatment-related factors [24]. The observed 5-year survival
rates [95% confidence intervals (CIs)] were 55% (52%-58%) for R0
and only 7% (3%-11%) for R1 and R2 resections. Following R0
resection, the 5-year survival rates varied according to the disease stages:
pT, 24%-74%, and pN, 33%-68% [24]. Moreover, according to the
stages, the 5-year survival rates (95% CIs) were 74% (68%-80%) for
stage I, 62% (56%-68%) for stage II, 40% (35%-45%) for stage III,
and 9% (0%-21%) for stage IV CRC. Based on the 5-year survival
rates (95% CIs), stage III CRC was prognostically inhomogeneous:
pN1, 47% (39%-55%), pN2 to 3, 34% (27%-41%; P b .01) [24].
The conventional pathological variables used for predicting
postoperative relapse in stage II CRC patients who have undergone
curative resection are as follows: the depth of tumor invasion (P b
.001), presence of vascular invasion (P b .001), presence of perineural
invasion (P = .048), and number of examined lymph nodes (P = .031)
[25]. Perineural invasion, a distinct pathological entity, is less
commonly observed among patients with CRC compared with
lymphovascular invasion [26]. Zorzos et al. reported a significant
association of perineural invasion with overexpression of
P-glycoprotein, a multidrug-resistant protein [27], in patients with
colon cancer; this partially clarified the significant role of perineural
invasion in CRC patients with systemic chemotherapy resistance
[27]. Poeschl et al. reported that perineural invasion in postoperative
specimens of CRC patients was significantly associated with several
histopathological variables indicating aggressive tumor behavior, such
as lymphatic invasion, venous invasion, tumor budding, an infiltrative
tumor growth pattern, and an incomplete tumor-free resection
margin [28]. The 5-year disease-free survival rates of patients with
perineural invasion (11%) were significantly poorer than those of
patients without perineural invasion (68%) [28]. Similarly, Lu et al.
reported that perineural invasion is a significant independent
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colon cancer [29].
Tumor Markers
The carcinoembryonic antigen (CEA) test measures the amount of
CEA—a protein that may appear in the blood of patients with certain
types of cancer, particularly CRC; it may also be present in patients
with pancreatic, breast, ovarian, or lung cancer. Pretherapeutic and
posttherapeutic increases in serum CEA levels among patients with
CRC can predict deeper local invasion of tumors, higher occult
metastasis risks, and higher posttherapeutic relapse rates [30,31].
Although CEA is a tumor marker widely used for following patients
with CRC, its lack of sensitivity has yet to be resolved. Sorbye and
Dahl [32] reported a transient CEA surge (15%; 4/27) in mCRC
patients receiving oxaliplatin-based chemotherapy; detection of this
inappropriate CEA elevation could inaccurately direct the therapeutic
protocol of a patient with CRC toward further disease progression.
The 2006 update of The American Society of Clinical Oncology
recommendations states that caution should be used when interpret-
ing an increased CEA levels during the first 4 to 6 weeks of a new
therapy because spurious early increases may occur, particularly after
oxaliplatin administration [33]. A retrospective study identified that
low serum albumin levels (P = .011), advanced UICC stage (P b
.001), and high serum CEA levels (P b .001) were independent
prognostic factors for cancer-specific survival. Furthermore, a
multivariate analysis showed that an age of ≥65 years, advanced
UICC stage, and high CEA levels (all P b .001) were independent
prognostic factors for overall survival [34]. Preoperative serum CEA
and albumin levels as well as age are supplementary to UICC staging
systems for predicting survival among stage II and III CRC patients
undergoing surgical treatment. In addition to the conventional UICC
staging system, considering the additional characteristics of the
prognostic factors might be imperative in patients with CRC before
surgical treatment.
Other Relevant Novel Pathological Factors
The collaborative study (RASCAL study) was to clarify the
association between KRAS mutations, patient outcome, and tumor
characteristics by use of data from CRC patients worldwide [35]. KRAS
gene mutations were associated with increased risk of relapse and death
in the RASCAL study [35]. The epidermal growth factor receptor
(EGFR) is a major therapeutic target in CRCs [36]. Activating
mutations of the KRAS gene stimulates the RAS/RAF/MAPK pathway
independent of EGFR activation; therefore, CRCs with KRAS
mutations are resistant to EGFR inhibitors [37]. CRC patients with
the BRAF mutation tend to have a poor prognosis [38,39].
Vascular endothelial growth factor (VEGF), a crucial predictor of
early postoperative relapse in patients with stage I to III CRC, may
facilitate identifying patients who would benefit from intensive
follow-up and therapeutic programs. VEGF overexpression can
predict not only early postoperative relapse but also disease-free
survival (P b .001) and overall survival (P = .002) [40]. However, the
coexistence of cyclin D1 and VEGF expression might be a poor
prognostic factor for stage I to III CRC patients after curative
resection [41]. Reduced peritherapeutic VEGF expression could be a
predictor of responsiveness to first-line FOLFIRI + bevacizumab
therapy in patients with mCRC [42].
Patients with mCRC expressing high EGFR levels are more likely
to exhibit higher progression-free and overall survival rates whentreated with cetuximab + chemotherapy (all P b .05) [43]. In 2013,
Huang et al. demonstrated that EGFR expression is of prognostic
value for patients with metachronous mCRC [44]. Positive EGFR
expression was a significant independent prognostic factor for
disease-free survival (hazard rate = 4.012; 95% CI, 1.130-8.445;
P = .006) and overall survival (hazard rate = 3.090; 95% CI,
1.477-10.900; P = .028) in patients with metachronous mCRC [44].
The genetic polymorphisms of excision repair cross‐complemen-
tation group 1 and X‐ray repair cross‐complementing protein 1 may
be useful in predicting clinical outcomes among Taiwanese mCRC
patients treated with FOLFOX-4 [45]. Furthermore, excision repair
cross‐complementation group 1 overexpression is a predictor of not
only early failure but also disease-free survival (P b .001) and overall
survival (P b .001) in stage III CRC patients undergoing FOLFOX-4
adjuvant chemotherapy [46].
Microsatellite instability (MSI) is a clonal change in the number of
repeated DNA nucleotide units in microsatellites. Although most
CRCs develop through a chromosomal instability pathway, approx-
imately 12% to 15% have deficient DNA mismatch repair (dMMR)
that is characterized in the tumor by MSI. Immunohistochemistry for
MMR proteins can be applied as a screening test or a supportive test
for MSI analysis [47]. 5-FU–based adjuvant chemotherapy does not
improve the outcome of stage II or III MSI tumors [48]. Available
data indicated that patients with stage II dMMR CRCs have an
excellent prognosis and do not benefit from 5-FU–based adjuvant
chemotherapy, which supports their recommended management
through surgery alone. By contrast, the benefit of the standard
adjuvant chemotherapy by using the FOLFOX regimen in patients
with stage III dMMR CRC requires further research; therefore, all
patients should be treated with standard adjuvant FOLFOX [49].
Cell-free DNA fragments are shed into the bloodstream by cells
undergoing apoptosis or necrosis, and the load of circulating cell-free
DNA (cfDNA) correlates with tumor staging and prognosis.
Moreover, recent advances in the sensitivity and accuracy of DNA
analyses have enabled genotyping of cfDNA for somatic genomic
alterations in tumors. The ability to detect and quantify tumor
mutations has proven effective in tracking tumor dynamics in real
time and as a liquid biopsy that can be used for various previously
unfeasible clinical and investigational applications [50]. In recent
years, cfDNA analysis as a potential screening test for CRC has
been the prime focus [51]. The detection of epigenetic and
genetic alterations in cfDNA, such as DNA methylation and
mutations, and related RNAs was reported to improve cancer
detection on the basis of unique, CRC-specific patterns.
CRC-specific nucleic acid biomarkers in peripheral blood can be
potential screening markers [51].
ComparisonofTraditionalMethodandArrayTechnique
for Detecting CTCs
Immunocytochemistry, Immunohistochemistry, and Reverse-
Transcriptase Polymerase Chain Reaction
CTCs are present in the peripheral blood and possess antigenic and
genetic characteristics of a specific tumor type [52]. Active
angiogenesis may occur in cancer tissues growing to 2 mm in
diameter [53]. CTCs are often detected in the blood of patients with
cancer [54–56]. The 2000s, the commonly used techniques for
detecting nucleic acid material in disseminated tumor cells, were
antibody-based assays (e.g., immunohistochemistry) [57,58] and
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(RT-PCR), and real-time quantitative PCR (Q-PCR) assays; these
enabled the sensitive detection of CTCs [55,59–61] and minute
quantities of tumor-related molecular markers in the peripheral blood
of patients with various early or advanced cancer type.
The diagnosis and therapy of early-stage CRC tumors can
potentially reduce the morbidity and mortality among patients with
CRC [24]. Membrane arrays can also considerably improve the
diagnosis rate of early-stage CRC [62]. In 2006, for CTC detection,
Wang et al. used RT-PCR to detect human telomerase reverse
transcriptase (hTERT), cytokeratin (CK)-19, CK-20, and CEA
mRNA in the peripheral blood of 72 patients with CRC and 30
healthy individuals [63]; their results revealed that RT-PCR is feasible
for detecting CEA mRNA and that it may be a promising tool for
early prediction of micrometastatic CTCs in patients with CRC [63].
Moreover, this postoperative CTC detection is helpful in the earlier
prediction of postoperative relapse in CRC patients with normal
perioperative serum CEA levels, with a median lead time of 6 months
before detection of actual elevated CEA levels [64]. These data
suggest that the development of a more effective marker than CEA
is required for monitoring the response of mCRC patients to
systemic therapy.
Because CTCs are usually found at very low frequencies in normal
peripheral blood mononuclear cells, tumor cell enrichment tech-
niques including density gradient centrifugation (Ficoll-Hypaque
separation) and immunomagnetic or size filtration procedures are
often used to enrich tumor cells before their detection [65,66].
Although immunocytochemistry enables the morphological assess-
ment of stained cells, molecular assays are generally more sensitive
[67,68]. The use of different methodologies for CTC detection has
shown conflicting results, and the lack of a standardized technology
impedes the implementation of CTC measurement in routine clinical
practice. In addition to the obvious and significant differences in
CTC detection rates among the molecular methods, such methods
entail analyzing only one molecular target per test [55,59–61].
Because of the heterogeneity of gene marker expression in peripheral
blood, multimarker assays are considered more reliable and sensitive
than single-marker assays are. [52,54,56,69]. A panel of molecular
markers analyzed using the gene chip technique would be necessary to
increase the sensitivity, specificity, and accuracy of CTC detection
[52]. Therefore, well-standardized detection methods for multiple
CTC-related markers are highly required.
Veridex's Cell Search Assay
CTCs were enumerated with immunomagnetic separation from
7.5 ml of blood by the CellSearch System (Veridex LLC, Raritan,
NJ), and the detection rate of no less than two CTCs occurred at 30%
(99 of 333) in CRCs [70]. CTCs were defined as epithelial cell
adhesion molecule isolated intact cells staining positive for cytokeratin
and negative for CD45, and the number of CTCs before and during
treatment was an independent predictor of progression-free survival
and overall survival in patients with mCRC [71]. Baseline CTC count
(N or =3 or b3 CTCs/7.5 ml of blood) was an important prognostic
factor within specific subgroups defined by treatment or patient
characteristics [72].
Membrane Arrays
Although we previously showed that real-time Q-PCR for CEA
mRNA could be a promising tool for early detection of micrometa-static CTCs [63], using it for detecting multiple markers can be time-
and labor-intensive procedures in clinical practice. In 2004,Wang et al.
suggested that identifying CTC DNA through molecular detection
of mutations in APC, KRAS, and TP53may facilitate early detection
of postoperative recurrence or metastases in patients with CRC [73].
In 2005, cDNA microarray technology was applied to identify
colorectal tumor–related functional genes, which were overexpressed
continuously from colorectal adenoma to adenocarcinoma [74]; in
this robust biochip assay, using a panel of informative mRNA markers
was imperative for simultaneous high-quality detection of CTC.
Among the 23 genes used, 22 were involved in cell motility, cell
adhesion, chemokine activity, signal transduction, cytoskeleton
organization, proteolysis, apoptosis, and cell proliferation [74]; the
identified genes provided valuable information regarding CRC
carcinogenesis and metastasis and represented potential novel targets
for new strategies of CRC diagnosis [74].
In 2006, our study group evaluated the simultaneous detection of
multiple mRNA markers by using a colorimetric membrane array
approach in the peripheral blood of CRC patients for early diagnosis
[62,75]. The identified CRC-related oligonucleotides were synthe-
sized and then spotted on a nylon membrane to construct a CRC
diagnostic genechip. Digoxigenin-labeled cDNA was amplified by
using RT-PCR from the peripheral blood of the patients with CRC
and hybridized to the gene chip. Consequently, hybridization signals
were detected through color development. Furthermore, Yeh et al.
constructed a CRC diagnostic gene chip including six markers
(CK-19, CK-20, CEA, REG4, uPA, and TIAM1 mRNA) for further
clinical evaluation; the sensitivity (88.8%), specificity (87.8%), and
accuracy (88.2%) of this membrane array-based diagnostic method
with multiple CRC markers were much higher than those of methods
entailing the use of single markers [62]. We demonstrated a
significantly high correlation between real-time Q-PCR and the
membrane array method in the detection of CTCs [75]; the
membrane array results were strongly associated with those of
real-time Q-PCR (P b .001), and the sensitivity and specificity of the
colorimetric membrane array method for CTC detection were 94.3%
and 94%, respectively [75]. The membrane array for detecting
CTC-related multiple mRNA markers from peripheral blood could
be used not only for early CRC diagnosis but also for postoperative
surveillance of patients with CRC [20,62,64,75].
Weighted Enzymatic Chip Array
Although the colorimetric membrane array method can be a
promising approach for the clinical detection of CTCs in patients
with CRC, its sensitivity, specificity, and accuracy must still be
improved. In the membrane array method, each gene is calculated
using the same value, and the corresponding outcome is interpreted;
however, this prevents the differentiation of the importance of genes
in the prognosis of specific diseases — a major limitation impeding
the clinical application of this technique [76]. In addition,
digoxigenin used on colorimetric membrane array platform is
expensive for laboratory diagnosis, and their operating technique
requires skill. Therefore, our research team developed a cheaper
new-generation gene chip operation platform that uses the
biotin-avidin enzyme system to replace the conventional digoxigenin
system. Furthermore, we weighted multiple target genes, those
involved in cancer development, on the same gene chip for improving
the accuracy of CTC detection and successfully established the
weighted enzymatic chip array (WEnCA) platform [77]. WEnCA has
Figure 1. CTC detection and characterization may be a valuable tool to refine prognosis, and CTCs can be predictive biomarkers.
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the use of this innovative, high-throughput technique with multiple
mRNA markers significantly improved the clinical diagnosis of early
CRC and distinguished patients with CRC from individuals with
sufficient accuracy and in shorter time and lower cost [76,77].
CTCs as Surrogate Markers for Determining Clinical
Outcomes of CRC
Chemotherapy Predictive Markers
A recurrence rate of approximately 30% has been reported among
colon cancer patients receiving the postoperative FOLFOX4 adjuvant
regimen [10,11]. Relapse in stage III CRC patients receiving
postoperative adjuvant chemotherapy is attributed mainly to reduced
response to the chemotherapeutic regimen. Therefore, detecting
CTCs can be valuable for identifying potential metastases earlier and
selecting chemotherapy-resistant patients who would benefit from
other therapeutic regimens.
The response of CRC patients to cetuximab can be determined
using the KRAS mutational status of the tumor [78]. We previously
developed membrane arrays as a promising tool to detect CTCs with
KRAS in patients with malignancies [20]. The detection of KRAS
mutations has been clinically applied to mCRC patients being treated
with cetuximab and FOLFOX4 or FOLFIRI (leucovorin +5-FU +
irinotecan) [79]. Patients with CTC carrying wild-type KRAS show
longer progression-free survival and overall survival when treated with
cetuximab + chemotherapy (P b .0001) [79]. The detection of KRAS
in peripheral blood may predict the response to cetuximab plus
chemotherapy in patients with mCRC [79]. These findings indicate
that the detection of KRAS mutational status in CTCs by using gene
expression array has potential clinical applications for selecting
mCRC patients who may benefit from cetuximab therapy.
The persistent presence of postchemotherapeutic CTCs is a
potential powerful surrogate marker for determining clinicaloutcomes in stage III colon cancer patients receiving adjuvant
mFOLFOX chemotherapy [29].
Prognostic Marker
CRC is a frequently lethal disease with heterogeneous outcomes and
drug responses. To resolve inconsistencies among the reported gene
expression–based CRC classifications and facilitate clinical translation,
Guinney et al. formed an international consortium dedicated to
large-scale data sharing and analytics across expert groups [80]. They
showed marked interconnectivity between six independent classifica-
tion systems coalescing into four consensus molecular subtypes (CMSs)
with distinguishing features: CMS1 (microsatellite instability immune,
14%), hypermutated, microsatellite unstable and strong immune
activation; CMS2 (canonical, 37%), epithelial, marked WNT and
MYC signaling activation; CMS3 (metabolic, 13%), epithelial and
evident metabolic dysregulation; and CMS4 (mesenchymal, 23%),
prominent transforming growth factor–beta activation, stromal
invasion, and angiogenesis. Samples withmixed features (13%) possibly
represent transition phenotype or intratumoral heterogeneity [80].
In advanced-stage CRC, the availability of CTCs may enable more
efficient disease monitoring, particularly in patients with mCRC
showing no measurable increase in the levels of CEA or other
markers. Our recent investigations have demonstrated that the
persistent presence of postoperative CTCs is a poor prognostic factor
for patients with CRC after curative resection [81,82].
The colorimetric membrane array method has been evaluated as a
potential diagnostic and postoperative surveillance tool for detecting
CTCs by using four mRNA markers (hTERT, CK-19, CK-20, and
CEA mRNA) in the peripheral blood of CRC patients with normal
perioperative serum CEA levels [64]. CRC patients expressing all four
mRNA markers showed significantly poorer survival rates than did
those expressing fewer than four markers. Therefore, membrane array
is helpful for early prediction of postoperative relapse in CRC patients
with normal CEA levels [64].
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diagnosed with UICC stage II CRC. However, up to 30% of patients
with stage II CRC relapse within 5 years of surgery because of
recurrent CRC or mCRC. Identifying reliable prognostic factors in
high-risk patients with stage II CRC patients is imperative. In 2007, a
colorimetric membrane array comprising a panel of mRNA markers
was used to detect CTCs in the peripheral blood of 194 patients with
stage II CRC for identifying a subgroup of patients at high risk for
relapse [25]; the study reported that the assay is a potential auxiliary
tool to conventional clinicopathological variables used for predicting
of postoperative relapse in stage II CRC patients who have undergone
curative resection [25]. In addition, Uen et al. and Lu et al. have
demonstrated that the persistent presence of postoperative CTCs is a
poor prognostic factor for patients with CRC after curative resection
[81–82]. In 2008, among 438 stage I to III CRC patients who
underwent curative resection, the persistent presence of CTCs was
strongly correlated with poorer relapse-free survival rates (all P b
.001) [81]. Similarly, the presence of persistent postoperative CTCs
was strongly correlated with poorer disease-free and overall survival
rates (both P b .001) in patients with UICC stage II/III colon cancer
patients [82].
Conclusions
CTC detection and characterization may be valuable tools to refine
prognosis, and CTCs can be predictive biomarkers in a real-time tumor
biopsy for designing individually tailored cancer therapy (Figure 1).
Through the detection of CTC-related mRNA markers, in addition to
Veridex's CellSearch assay, the gene chip techniques, including
membrane array and WEnCA, are reliable for early diagnosis and
prognosis prediction in patients with CRC. In addition to the
assessments of pathological marker (e.g., perineural invasion and
lymphovascular invasion) or traditional tumor marker (e.g., serum
CEA) levels, the persistent presence of posttherapeutic CTCs in CRC
patients is a potentially valuable tool for predicting relapse. These tools
might gender therapeutic considerations and options such as curative
surgery, prolonged adjuvant chemotherapy and radiotherapy durations,
as well as change in therapeutic agents. However, additional validation
studies are warranted for applying CTCs as prognostic factors or
therapeutic strategies and for developing new biomarkers for CRC.
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